6/5/26
What the Ozempic Boom Is Masking About the Pharma Industry
What the Ozempic Boom Is Masking About the Pharma Industry
In just a few years, GLP-1 drugs, the injectable medicines behind household names like Ozempic, Wegovy and Zepbound, have gone from niche treatments for type 2 diabetes to one of the most talked-about product categories in the world.
Millions of people are taking them - and billions of dollars are flowing into the companies that make them.
But a new report from Deloitte is asking an uncomfortable question: what happens to pharma's numbers if you take the weight loss drugs out?
The answer isn’t reassuring for investors.
Here's what the data shows, and what you should keep in mind.
How Much of Pharma's Growth Is Really Just GLP-1s?
GLP-1s are the class of drugs behind Ozempic and Wegovy. They work by mimicking hormones that regulate appetite and blood sugar, and have expanded rapidly from diabetes treatment into weight loss, cardiovascular care, kidney disease, sleep apnea, and more.
Their commercial impact has been extraordinary.
Before we get into the numbers, it's worth noting that these drugs exist in a culture that has long treated weight loss as automatically desirable. GLP-1s offer real medical benefits for many people, but the financial boom around them is partly driven by fatphobia, not science alone.
Even the term 'obesity' itself remains medically controversial - experts debate whether it truly qualifies as a disease, and the diagnostic criteria rely on BMI, a problematic measurement system that was never designed to assess individual health.
I'll focus on the investor angle here, but that context has to be acknowledged.
With that said, here's what the new Deloitte report showed:
Pharma R&D returns for the world's top 20 drugmakers have risen for the third consecutive year, reaching about 7%, the highest level in years.
For the first time in 16 years, obesity treatments have overtaken cancer as the largest contributor to late-stage pipeline value.
GLP-1 and related obesity drugs now account for around 38% of all projected future cash flows from the 2025 late-stage pipeline, up from just 1% in 2022.
That's a remarkable shift in three years.
But when you strip out the GLP-1 drugs, the industry's R&D return drops from 7% to about 2.9%, actually lower than the year before. In other words, without the weight loss drug boom, the rest of pharma's pipeline looks weaker than it did a year ago.
Deloitte also found a small cluster of around 54 drug programmes - 9% of all late-stage assets being developed - are expected to generate roughly 70% of total future sales across the whole sector. That’s a huge amount of value is resting on a very small number of bets.
Why Deloitte Calls It a “Bubble Effect”
Deloitte isn't saying GLP-1 drugs are going away - the concern is about concentration.
Think about it the same way we think about diversifying a portfolio. When too much of your value is tied to one theme, one shock can affect everything. That's what's happening inside pharma right now.
A bubble effect, in this context, means too much financial value is now piled into one area. And when that happens, any disruption to that area ripples through the entire sector.
Disruptions like tougher pricing decisions by governments and insurers, a new competitor with a more effective or cheaper drug, unexpected safety data, or a policy shift on reimbursement - any of these could affect not just one company, but the headline numbers for pharma as a whole.
What This Means for Long-Term Investors
The GLP-1 boom is one of the most dramatic examples in recent memory of how quickly a single scientific breakthrough can reshape an entire industry's numbers. Three years ago, obesity drugs contributed 1% of projected pipeline value.
Today, they're the single largest driver.
When you look at healthcare sector performance, it's worth knowing that the health of the sector right now is heavily tied to one scientific thesis: obesity and metabolic disease.
The GLP-1 story isn't over, but understanding what's driving your returns is always better than being surprised by them.
Sources: